Help us: Donate
Follow us on:

Underdog Pharmaceuticals Receives Accelerated Designation

UDP-003 may represent a breakthrough in the treatment of atherosclerosis.


Underdog Pharmaceuticals has just issued a press release announcing that UDP-003, a compound being studied for its effectiveness against oxidized cholesterol, has been given an Innovation Passport under the UK’s Innovative Licensing and Access Pathway program. This is similar to the Fast Track designation given by the FDA in the United States.

Underdog is a spin-out company from SENS Research Foundation, and Matthew O’Connor, who is quoted in this article, is well-known for his previous activities at SRF. We have previously reported on Underdog’s efforts in combating oxidized cholesterol, and we look forward to the success of this project.

Mountain View, CA, U.S., September 8, 2021 –

Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been awarded an Innovation Passport under the United Kingdomโ€™s Innovative Licensing and Access Pathway (ILAP), to pursue fast patient access to its groundbreaking treatment for cardiovascular disease.

Accounting for more than 40% of deaths in Europe and the United States, and with annual treatment costs more than ยฃ29 billion in the UK alone, cardiovascular disease is by far the worldโ€™s most life-threatening condition, and its primary cause is atherosclerosis. Underdogโ€™s engineered synthetic carbohydrate compound, UDP-003, is designed to target and remove toxic oxidized cholesterol, a key driver of arterial plaque accumulation. Underdog is one of the first companies, and UDP-003 one of the very few pre-clinical therapies, to receive an ILAP designation.

ILAP, introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) in January, is designed to accelerate development of and access to promising medicines of significant potential public health benefit. The program provides enhanced early input and interactions with MHRA, the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the National Health Service (NHS). The ILAP program also provides the potential for significant downstream regulatory advantages, including rolling clinical reviews, accelerated assessment, and supervised early reimbursed use under adaptive authorization.

โ€œThis is an honor for us and a wonderful step forward for our program,โ€ said Matthew S. Oโ€™Connor, Underdog CEO of Scientific Affairs. โ€œThere is an enormous public need for drugs which can significantly reverse established atherosclerosis, rather than manage or delay its onset.โ€

โ€œI believe the MHRA is sending a powerful message by reviewing and admitting preclinical stage programs like UDP-003 into ILAP,โ€ noted Mike Kope, Underdog CEO of Corporate Affairs. โ€œWeโ€™re pursuing a new target, with a new compound and seeking evidence of genuine disease modification; and though the potential is fascinating, the clinical challenges are real. The advice and consultation weโ€™ll receive will be invaluable to the success of the program.โ€

About Underdog

Underdog Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit or send an email to [email protected]

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Companyโ€™s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.


Mike Kope


Underdog Pharmaceuticals Inc

[email protected]

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if itโ€™s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Rejuvenation Startup Summit 2024: May 10-11 in Berlin

Berlin, Germany - May, 23, 2023 - The Forever Healthy Foundation is pleased to announce the second edition of the...

The SynBioBeta Conference is Almost Here

  At Oakland Marriott, California May 23-25, the SynBioBeta Global Synthetic Biology Conference is happening. This is a three-day event...

Annoucing the International Longevity Summit in Africa

On August 23-24, the International Longevity Summit is happening in Johannesburg, South Africa. It will be a convergence of global...

Longevity Summit Dublin

The organizers of Longevity Summit Dublin have issued a brief press release encouraging people to come to this August conference....

No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.